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Abstract
Background: The impact on carriage and optimal schedule for primary vaccination of older children with 10-valent
pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) are unknown.
Methods: 600 Kenyan children aged 12–59 months were vaccinated at days 0, 60 and 180 in a double-blind randomized
controlled trial according to the following vaccine sequence: Group A: PHiD-CV, PHiD-CV, diphtheria/tetanus/acellular
pertussis vaccine (DTaP); Group B: PHiD-CV, DTaP, PHiD-CV; Group C: hepatitis A vaccine (HAV), DTaP, HAV. Nasopharyngeal
carriage of Streptococcus pneumoniae was measured at five timepoints. In 375 subjects, serotype-specific responses were
measured by 22F-inhibition ELISA and opsonophagocytic killing assays (OPA) one month after vaccination.
Results: Following one dose of PHiD-CV,.90% of recipients developed IgG$0.35 mg/mL to serotypes 1, 4, 5, 7F, 9V and 18C
and OPA$8 to serotypes 4, 7F, 9V, 18C, 23F. After a second dose .90% of recipients had IgG$0.35 mg/mL to all vaccine
serotypes and OPA$8 to all vaccine serotypes except 1 and 6B. At day 180, carriage of vaccine-type pneumococci was 21%
in recipients of two doses of PHiD-CV (Group A) compared to 31% in controls (p = 0.04). Fever after dose 1 was reported by
41% of PHiD-CV recipients compared to 26% of HAV recipients (p,0.001). Other local and systemic adverse experiences
were similar between groups.
Conclusions: Vaccination of children aged 12–59 months with two doses of PHiD-CV two to six months apart was
immunogenic, reduced vaccine-type pneumococcal carriage and was well-tolerated. Administration of PHiD-CV would be
expected to provide effective protection against vaccine-type disease.
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Background
Invasive pneumococcal disease (IPD) is a major cause of
morbidity and mortality in Kenya [1,2]. In countries where
pneumococcal conjugate vaccine (PCV) has been introduced into
the childhood immunization schedule, it has reduced the incidence
of vaccine-type IPD by more than 75% among young children
[3,4]. Reductions in IPD among unvaccinated children and adults
have also been achieved through decreased transmission of
pneumococcal infection from vaccinated children [3,5,6]. The
first generation PCV offered protection against seven (4, 6B, 9V,
14, 18C, 19F, and 23F) of the more than 90 known pneumococcal
serotypes. A 10-valent pneumococcal non-typeable Haemophilus
influenzae protein D conjugate vaccine (PHiD-CV) extended the
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coverage to serotypes 1, 5, and 7F, which cause a significant
proportion of IPD in the developing world. PHiD-CV was licensed
for use in children ,2 years of age in 2009, following studies that
demonstrated an immunogenicity profile comparable to that of
PCV7 and acceptable safety and immunogenicity when co-
administered with other paediatric vaccinations [7–9] and it has
since been demonstrated to protect against IPD [10].
Catch-up vaccination in addition to routine vaccination of
infants has been found to be an effective strategy to more rapidly
achieve the population-level benefits of vaccination and extend
protection to older children, who bear a substantial part of the
burden of vaccine-preventable childhood diseases. The Kenya
Ministry of Public Health and Sanitation introduced PHiD-CV
into the routine infant vaccination programme in 2011, with a
catch-up campaign in two districts to provide PHiD-CV to
children 12–59 months of age. Because PHiD-CV was not licensed
for use in children older than 23 months of age at that time, we
aimed to assess the immunogenicity, impact on carriage, and
reactogenicity of primary vaccination with PHiD-CV in children
aged 12–59 months prior to the national introduction of the
Figure 1. Trial profile.
doi:10.1371/journal.pone.0085459.g001
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vaccine. We specifically aimed to evaluate whether one or two
doses were required for a robust immune response and to reduce
carriage. We also assessed whether the timing of the second dose
had an impact on the response.
Materials and Methods
Population and Study Design
This phase III double-blind randomized controlled trial
involving children aged 12–59 months was conducted between
January–September 2010 in Malindi District, Kenya
(NCT01028326). The protocol was approved by the Oxford
Tropical Ethical Review Committee (No. 54-09) and the Kenya
National Ethical Review Committee (SSC1635). The protocol for
this trial and the supporting CONSORT checklist are available as
supporting information (Protocol S1 and Checklist S1). Children
were recruited at one of two health dispensaries in a rural area of
Malindi District on the Kenyan coast. Humidity is high and there
are two annual rainy seasons, April through July and November
through December. The area is endemic for malaria, with
declining transmission over the last 10 years. H. influenzae type b
vaccine, given with diphtheria and tetanus toxoids and pertussis
vaccine to infants after 6, 10 and 14 weeks, was introduced in
2001. Written informed consent was obtained from the parent or
guardian of each subject prior to participation. Children were
considered eligible if they did not have a serious medical condition
(e.g., severe malnutrition, HIV infection, malignancy) and had not
received pneumococcal conjugate vaccine or hepatitis A vaccine
(HAV) from birth, or any dose of vaccine against diphtheria,
tetanus, or pertussis after the first birthday.
Vaccine and Schedules
Eligible children were assigned into the appropriate age stratum
(12–23 months, 24–35 months, 36–47 months or 48–59 months)
and one of three vaccination regimens using a computer-generated
block randomization scheme that was generated by the study
sponsor before the start of the trial (block size = 6). The study nurse
assigned children sequentially to the next available study number.
Vaccines were administered in the left deltoid muscle on days 0, 60
and 180 (Figure 1) and the sequence was PHiD-CV, PHiD-CV,
diphtheria/tetanus/acellular pertussis vaccine (DTaP) in Group A;
PHiD-CV, DTaP, PHiD-CV in Group B; hepatitis A vaccine
(HAV), DTaP, HAV in Group C (i.e., the control group). Vaccines
were provided by GlaxoSmithKline Vaccines in pre-filled syringes
labelled with the randomization number and dose number;
syringes were indistinguishable. The study group assignment was
unblinded by the study nurse on day 180 and one dose of PHiD-
CV was administered to all subjects in the control group.
Immunogenicity
In a subset of 375 children (all subjects aged 12–23 months and
the first 25 subjects enrolled into each study group for each of the
older 3 age strata), blood was collected prior to vaccination,
30 days after the first vaccine visit, and either 30 days after the
second vaccine visit (on day 90; Groups A, C) or 30 days after the
third vaccine visit (day 210; Group B). Plasma samples were stored
at 220uC or colder until analyzed.
Serotype-specific anti-capsular IgG concentrations to each of
the 10 vaccine serotypes were measured by 22F-inhibition ELISA,
i.e following adsorption with cell wall polysaccharide and 22F
polysaccharide, in the WHO Pneumococcal Serology Reference
Laboratory at the Institute of Child Health, University College,
London [11].
The functional capacity of antibody to each of the 10 vaccine
serotypes was measured by opsonophagocytic activity (OPA) using
a modification of the HL-60 cell WHO reference method in the
SGS laboratory, Belgium [12,13]. Viable colony counts were
performed after the plates were incubated overnight at 37uC in
5% CO2 atmosphere. OPA titers are expressed as the reciprocal of
the serum dilution able to sustain $50% bacterial killing.
Nasopharyngeal Carriage
Nasopharyngeal (NP) rayon swabs (Medical Wire Co, UK) were
collected from all subjects at enrolment, days 30, 60, 90 (Groups A
and C only) and day 180. Specimens were collected by passing the
swab through the nostril, along the floor of the nasal cavity until it
touched the posterior nasopharyngeal wall, where it was left for 2–3
seconds, rotated, and removed. Swabs were placed in skim-milk
tryptone glucose glycerol (STGG) media and processed at the
KEMRI- Wellcome Trust Programme laboratory in Kilifi, Kenya,
in accordance with WHO recommendations [14]. Isolates of
Streptococcus pneumoniae and H. influenzae were identified by standard
microbiological methods. Pneumococci were identified from genta-
micin-blood agar by optochin susceptibility testing; serotyping was
performed by latex agglutination and the Quellung reaction. Typing
ofH. influenzae was performed by multiplex PCR using an IgA target
that discriminates between H. influenzae and Haemophilus haemolyticus
[15] and a bexA target to determine capsular type [16].
Table 1. Participant Characteristics.
Characteristic All groups Group A Group B Group C
n (%) n (%) n (%) n (%)
Male 297 (49.5) 99 (49.5) 102 (51) 96 (48)
MUAC (median, IQR) 15 (14.3–15.8) 15 (14.3–15.8) 15 (14.2–15.9) 15 (14.3–15.8)
Had three doses of Pentavalent vaccine 585 (97.5) 193 (96.5) 195 (97.5) 197 (98.5)
Had at least one dose of Measles vaccine 572 (95.3) 186 (93.0) 192 (96.0) 194 (97.0)
Age group 12–23 months 142 (23.7) 47 (23.5) 47 (23.5) 48 (24.0)
Age group 24–35 months 153 (25.5) 50 (25.0) 55 (27.5) 48 (24.0)
Age group 36–47 months 151 (25.2) 50 (25.0) 50 (25.0) 51 (25.5)
Age group 48–59 months 154 (25.7) 53 (26.5) 48 (24.0) 53 (26.5)
MUAC=mid upper arm circumference.
IQR = interquartile range.
doi:10.1371/journal.pone.0085459.t001
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Figure 3. Pneumococcal serotype-specific opsonophagocytic activity geometric mean titer before and after PHiD-CV or control
vaccine. Pneumococcal serotype-specific opsonophagocytic activity geometric mean titer and 95% confidence interval among children aged 12–59
months before and after PHiD-CV (Groups A and B) or control vaccine (Group C). Group A N (range) by day: day 0 (0–110); day 30 (66–124); day 90
(104–121) Group B N (range) by day: day 0 (0–102); day 30 (60–119); day 210 (97–115) Group C N (range) by day: day 0 (3–109); day 30 (2–118); day 90
(2–118) Results for serotype 5 at day 0 not available because of insufficient specimen volume.
doi:10.1371/journal.pone.0085459.g003
Figure 2. Pneumococcal serotype-specific IgG geometric mean concentration before and after PHiD-CV or control vaccine.
Pneumococcal serotype-specific IgG geometric mean concentration with 95% confidence interval among children aged 12–59 months before and
after PHiD-CV (Groups A and B) or control vaccine (Group C). Group A N (range) by day for GMC: day 0 (125–127); day 30 (124); day 90 (120–122)
Group B N (range) by day for GMC: day 0 (121–124); day 30 (119–120); day 210 (101–115) Group C N (range) by day for GMC: day 0 (121–124); day 30
(119–121); day 90 (117–119).
doi:10.1371/journal.pone.0085459.g002
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Reactogenicity
Study personnel assessed all subjects 30 minutes after every dose
and three days after doses 1 and 2 and documented observed local
and systemic adverse events. In addition, study personnel
interviewed parents/guardians to determine the subject’s peak
local and systemic adverse events in the three days following doses
1 and 2. For efficiency of design, reactogenicity was not assessed
three days after dose 3. Serious adverse events were recorded for
all subjects throughout the study.
Statistical Analysis
The primary outcomes were carriage and immunogenicity after
two doses of PHiD-CV. The sample size was determined for these
outcomes. Given an estimated background prevalence of naso-
pharyngeal carriage of the PHiD-CV serotypes of 25% in children
in coastal Kenya, a sample size of 200 in each group would give
90% power (alpha = 0.05) to detect a difference in the vaccine-type
(i.e., serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) carriage
prevalence of 12% in recipients of 1 or 2 doses of PHiD-CV and
25% in controls, allowing for 10% attrition. With a sample size of
100 children who received PHiD-CV at study day 0 and day 60 or
180, the 95% confidence interval for finding that 95% achieved
the protective antibody threshold would be 89%–98%, allowing
for 10% attrition. The sample size was therefore set at 600
children (50 children in each of four age groups in each of three
vaccine regimens), with a subset of 375 children followed for
immunological evaluation of blood (50 children aged 12–23
months in each of the three vaccine regimens and 25 children in
each of the three vaccine regimens for the older age groups). Given
this sample size, the study had 88% power to detect a difference in
the proportion of children that developed a seroprotective
antibody concentration following one dose of vaccine of 90%,
compared to 99% in those receiving a second dose of vaccine.
Anti-pneumococcal IgG concentrations and OPA titers were
log-transformed for analysis. Differences between Groups A and B
were tested and, if appropriate, data from these two groups were
combined for analysis. Immunogenicity following one dose versus
two doses of PHiD-CV was compared by a paired t-test of log
values. NP carriage prevalence was compared between groups
using the Chi-square test. The vaccine efficacy against carriage
and its 95% confidence interval was calculated as 1 minus the age-
adjusted odds ratio of carriage in PHiD-CV recipients compared
to control vaccine recipients. Solicited adverse experiences were
compared between groups using the Chi-square test or Fisher’s
exact test. Results were interpreted using two-sided p-values for
pre-specified hypotheses, with a p-value ,0.05 interpreted as
significant. No adjustment was made for multiple comparisons. All
analyses were performed on the total vaccinated cohort. Statistical
analysis was performed using STATA 11.
Figure 4. Proportion of participants with serotype-specific IgG $0.35 mcg/mL (A) and OPA$8 (B). Proportion of children aged 12–59
months with serotype-specific IgG $0.35 mcg/mL (A) and OPA$8 (B) at baseline and following one and two doses of PHiD-CV. Results for Groups A
and B were similar so combined results are presented. Numbers of subjects sampled are shown in Figure 2 and Figure 3. See also Tables S1 and S2.
*Serotypes for which the confidence intervals are non-overlapping for proportions meeting the specified threshold post-dose 1 and post-dose 2.
doi:10.1371/journal.pone.0085459.g004
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Results
Study Population
There were 600 Kenyan children (200 in each vaccination
regimen) recruited during January–February 2010, of whom 584
completed the study (10 withdrew consent, four moved from the
study area, and two were withdrawn because of an enrolment
error; Figure 1). Subject characteristics were similar for the three
study groups with males comprising 48–51% of each group and an
even distribution of children in each age stratum across study
groups (24–28% per stratum per group) (Table 1). Attendance
during the study was high with over 97% of subjects attending the
scheduled visits.
Immunogenicity Subset
375 children were enrolled in the immunogenicity cohort.
Median day of follow-up blood specimen collection was as follows:
day 30 (range 25–35), day 88 (range 84–97; Groups A and C); day
210 (range 198–216; Group B).
Baseline serotype-specific anti-capsular IgG geometric mean
concentrations (GMCs) and OPA geometric mean titers (GMTs)
were similar for the three study groups (Figures 2 and 3). Following
one dose of PHiD-CV, the IgG GMCs for all vaccine serotypes
and OPA GMTs for five serotypes were significantly higher in
PHiD-CV recipients compared to recipients of control vaccine. In
paired analysis, a significant increase in IgG GMC was observed
following a second dose of PHiD-CV for serotypes 1, 5, 6B, 14,
19F and 23F; an increase for serotypes 7F, 9V and 18C was also
observed but only in Group A subjects (Table 2). The post-dose
2 GMCs were similar between Group A (PHiD-CV given two
months after dose 1) and Group B (PHiD-CV given six months
after dose 1) for all serotypes except for significantly higher GMCs
for serotype 7F in Group A and for serotype 19F in Group B
(Figure 2). In paired analysis, there was a significant increase in
OPA GMTs following a second dose for serotypes 1, 5, 9V, 14,
and 19F; an increase for serotype 23F was also observed but only
in Group B subjects (Table 2). Of note, the OPA GMTs in
recipients of two doses of PHiD-CV were not significantly different
than in controls for serotypes 5, 6B and 23F (Figure 3).
At day 30, the proportion of subjects with serotype-specific
IgG$0.35 mcg/mL and OPA$8 was significantly higher in
PHiD-CV recipients compared to controls for all serotypes except
for OPA for serotype 7F, for which 100% of participants had
OPA$8 at all timepoints (Tables S1 and S2). Following one dose
of PHiD-CV, .90% of recipients (Group A and Group B)
developed IgG$0.35 mg/mL to serotypes 1, 4, 5, 7F, 9V and 18C
and OPA$8 to serotypes 4, 7F, 9V, 18C, and 23F (Figure 4). After
a second dose, .90% of recipients (Group A and Group B) had
IgG$0.35 mg/mL to all vaccine serotypes and OPA$8 to all
vaccine serotypes except 1 and 6B. The proportions of subjects
above the pre-specified thresholds were similar regardless of
whether the second dose was given two or six months after the first
dose.
In exploratory analysis, the antibody GMCs and/or proportion
of subjects with IgG$0.35 mcg/mL after one dose of PHiD-CV
were statistically significantly lower in children aged 12–23
months, compared to children aged 24–59 months for serotypes
1, 6B, 14, 19F, and 23F. A significant difference between age
groups was not observed after a second dose except for lower
antibody GMCs for serotype 14 in the younger age group (Table
S3).
Nasopharyngeal Carriage
No major differences in the nasopharyngeal carriage prevalence
of S. pneumoniae were observed between groups at day 0 (Figure 5;
Table S4). At day 60, vaccine-type pneumococcal carriage
prevalence was lower among PHiD-CV recipients compared to
control subjects (Groups A/B 16% vs Group C 30%, p-
value,0.001). Vaccine-type pneumococcal carriage was also
lower at day 180 among PHiD-CV recipients compared to
controls (Group A 21% vs Group C 31%, p-value = 0.04; Group B
Figure 5. Nasopharyngeal carriage among children aged 12–59
months before and after PHiD-CV or control vaccine. Nasopha-
ryngeal carriage of vaccine-type pneumococci (A), non-vaccine type
pneumococci (B) and non-typeable H. influenzae (C) among children
aged 12–59 months before and after PHiD-CV or control vaccine.
N = 192–200 subjects per group per timepoint. See also Table S4.
*p-value ,0.05, comparing carriage between Group A and Group C.
#p-value ,0.05, comparing carriage between Group B and Group C.
doi:10.1371/journal.pone.0085459.g005
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22% vs Group C 31%, p-value = 0.07). This translates to a vaccine
efficacy against vaccine-type carriage of 40% (94% CI: 4, 62) for
Group A (ie subjects who had received two doses of PHiD-CV),
and 36% (95% CI: 21, 60) for Group B (ie subjects who had
received one dose of PHiD-CV). The carriage prevalence of non-
vaccine type pneumococci was not significantly different in PHiD-
CV recipients compared to controls at any timepoint.
No statistically significant differences in the carriage prevalence
of non-typeable H. influenzae (NTHi) were observed between
groups with the exception of lower carriage among Group B
PHiD-CV recipients compared to controls at day 180 (Group B
56% vs Group C 66%; p= 0.04) (Figure 5; Table S4).
In exploratory analysis, the effect of nasopharyngeal carriage on
the IgG and OPA response at day 30, 90 and 210 was analyzed for
the four serotypes most commonly carried at day 0 among subjects
in Groups A and B (i.e., serotypes 6B, 14, 19F, and 23F). There
was no significant difference in the IgG GMCs and OPA GMTs of
carriers and non-carriers with the exception of serotype 19F for
which lower GMCs and GMTs were observed among carriers at
day 30, day 90, and 210 and for serotype 6B, for which lower
GMCs were observed at day 210 (data not shown).
Reactogenicity
Information on local and systemic adverse experiences in the
three days following vaccination was available for 600 subjects
following dose 1 and for 587 subjects following dose 2. Fever was
reported after dose 1 by 41% of PHiD-CV recipients compared to
26% children who received hepatitis A vaccine. Other local and
systemic adverse experiences following vaccination were in the
same range for the various groups after the first and second doses
of vaccine (Table 3).
There were no reports of grade 3 local adverse experiences
(swelling .30 mm, redness .30 mm, pain that prevented use of
the arm). Grade 3 drowsiness (drowsiness significant enough to
prevent normal activities) was reported in one child during the
3 days following the first vaccination with PHiD-CV. A temper-
ature of 39.0–39.4uC was documented following hepatitis A
vaccine on one occasion and DTaP on one occasion; no child had
a temperature $39.5uC.
A total of seven serious adverse events (SAEs) were reported in
six subjects. SAEs were documented in five (1.3%) of 400 children
who received PHiD-CV and one (0.5%) of 200 children in the
control group. One subject died after being struck by a car
approximately 4 hours after receiving the final study vaccination
(PHiD-CV). All SAEs were considered to be unrelated to
vaccination.
Discussion
Countries aiming to include pneumococcal vaccination in the
routine infant immunization schedule must consider whether or
not to conduct a catch-up campaign to extend protection to older
children and accelerate the population-level indirect benefits of
vaccine use. In this study, we found that administration of PHiD-
CV to children aged 12–59 months was immunogenic, reduced
nasopharyngeal carriage of vaccine-type pneumococci and was
well-tolerated. The immunogenicity of catch-up vaccination with
PHiD-CV has been documented in several studies[17–20];
however, this is the first study to demonstrate reductions in
Table 3. Solicited adverse events among children aged 12–59 months during the three days following dose 1 or dose 2 of PHiD-
CV or control vaccine.
Post-dose 1 Group A: PHiD CV Group B: PHiD-CV Group C: HAV Group AB combined p-value*
Sign/Symptom n % LL UL n % LL UL n % LL UL n % LL UL AB vs C
Any swelling 97 48.5 41.4 55.7 101 50.5 43.4 57.6 87 43.5 36.5 50.7 198 49.5 44.5 54.5 0.17
Any pain 166 83.0 77.1 87.9 172 86.0 80.4 90.5 157 78.5 72.2 84.0 338 84.5 80.6 87.9 0.07
Any redness 19 9.5 5.8 14.4 25 12.5 8.3 17.9 16 8.0 4.6 12.7 44 11.0 8.1 14.5 0.25
Any irritability 130 65.0 58.0 71.6 134 67.0 60.0 73.5 131 65.5 58.5 72.1 264 66.0 61.1 70.6 0.90
Any drowsiness 15 7.5 4.3 12.1 15 7.5 4.3 12.1 12 6.0 3.1 10.2 30 7.5 5.1 10.5 0.50
Any fever 80 40.0 33.2 47.1 83 41.5 34.6 48.7 52 26.0 20.1 32.7 163 40.8 35.9 45.7 ,0.001
Any local reaction 171 85.5 79.8 90.1 176 88.0 82.7 92.2 166 83.0 77.1 87.9 347 86.8 83.0 89.9 0.22
Any systemic reaction 159 79.5 73.2 84.9 163 81.5 75.4 86.6 145 72.5 65.8 78.6 322 80.5 76.3 84.3 0.03
Post-dose 2 Group A: PHiD-CV Group B: DTaP Group C: DTaP Group BC combined p-value*
Sign/Symptom n % LL UL n % LL UL n % LL UL n % LL UL A vs BC
Any swelling 35 17.8 12.7 23.8 37 19.1 13.8 25.3 33 16.8 11.9 22.8 70 17.9 14.3 22.1 0.96
Any pain 80 40.6 33.7 47.8 65 33.5 26.9 40.6 75 38.3 31.4 45.5 140 35.9 31.1 40.9 0.27
Any redness 1 0.5 0 2.8 0 0.0 0.0 1.9 2 1.0 0.1 3.6 2 0.5 0.1 1.8 1.00
Any irritability 26 13.2 8.8 18.7 22 11.3 7.2 16.7 16 8.2 4.7 12.9 38 9.7 7.0 13.1 0.21
Any drowsiness 2 1.0 0.1 3.6 2 1.0 0.1 3.7 3 1.5 0.3 4.4 5 1.3 0.4 3.0 1.00
Any fever 53 26.9 20.8 33.7 55 28.4 22.1 35.2 60 30.6 24.2 37.6 115 29.5 25.0 34.3 0.51
Any local reaction 95 48.2 41.1 55.4 86 44.3 37.2 51.6 86 43.9 36.8 51.1 172 44.1 39.1 49.2 0.34
Any systemic reaction 72 36.5 29.8 43.7 73 37.6 30.8 44.9 75 38.3 31.4 45.5 148 37.9 33.1 43.0 0.74
LL = lower limit of 95% confidence interval; UL = upper limit of 95% confidence interval.
*Chi-square p-value or, if cell size ,5, Fisher’s exact p-value.
doi:10.1371/journal.pone.0085459.t003
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carriage following catch-up vaccination in a developing world
setting and to compare the immunogenicity of one versus two
doses of vaccine.
Nasopharyngeal carriage of pneumococcus has been shown to
be a key event in the pathogenesis of IPD [21,22] and reductions
in carriage among vaccinated children have been associated with
reductions in carriage and IPD at the population level [23].
Among children aged 12–59 months, we found that nasopharyn-
geal carriage of vaccine-type pneumococci began to drop within
one month of the first dose of PHiD-CV and that the reductions
were statistically significant just two months following vaccination.
This effect was sustained through 6 months post-vaccination,
although the reduction was only statistically significant in children
who had received two doses of PHiD-CV. Dagan et al also
assessed the impact of catch-up dosing on carriage of vaccine-type
pneumococci, albeit with a different study design and different
vaccine formulation, and found similar results among toddlers in
Israel followed for 24 months after vaccination with one or two
doses of a nine-valent PCV or control vaccine (odds ratio for
vaccine-type carriage was 0.50 [0.38–0.66]) [24]. Consistent with
other trials, we did not observe an obvious impact of vaccination
on carriage of NTHi [25–27]. In contrast, carriage surveys
conducted in Kilifi, Kenya two years before and two years after
introduction of PHiD-CV into the routine childhood vaccination
schedule, accompanied by a catch-up campaign, revealed
significant reductions in NTHi carriage [28]. Widespread,
programmatic use of a vaccine might result in a greater impact
on carriage than is observed in individually-randomized clinical
trials because mass vaccination changes not only the susceptibility
of the vaccinated individual to carriage, but also the exposure of all
individuals in the community through indirect effects.
The immune response (IgG GMC, OPA GMT and proportion
above pre-specified thresholds) was generally higher following the
second versus the first dose of PHiD-CV, although this varied by
serotype. A threshold of serotype-specific IgG $0.35 mcg/mL
following primary vaccination has been established as the non-
inferiority threshold for comparison and licensure of new PCV
products [29,30]. It has been suggested that OPA $8 can better
predict protection against IPD [31]. The clinical relevance of these
thresholds is unclear in older children receiving a catch-up
schedule. A second dose of PHiD-CV was required to bring the
proportion of subjects with serotype-specific IgG $0.35 mcg/mL
above 90% for serotypes 6B, 14 and 23F and with serotype-
specific OPA $8 above 80% for serotypes 1, 5, 6B, 14 and 19F.
An increase in antibody GMC did not always correspond with an
increase in OPA GMT; however, our ability to interpret these
findings is limited by low sample size for some serotypes for the
OPA assay. Additional work is needed to understand the
relationship between these two measures and the association
between OPA and protection from IPD. Responses were generally
similar regardless of whether the second dose of PHiD-CV was
given 2 or 6 months after the first dose. Importantly, children in
the youngest age group had significantly lower antibody responses
compared to older children following a single dose of PHiD-CV
for several serotypes. A second dose proved particularly beneficial
in younger children and for generation of functional antibody to
several serotypes that are important causes of IPD locally.
As in other studies of catch-up vaccination with PHiD-CV, we
found that the immune responses to 6B and 23F were less robust
compared to other vaccine serotypes [17,18,20]. Although the
serotype-specific antibody concentrations in this study were lower
than observed following 1 or 2 doses of 9-valent PCV in UK
toddlers, the proportions achieving the threshold of $0.35 mcg/
mL for each serotype were comparable [32]. Antibody GMCs
following one dose of vaccine in 12–23 month olds in our study
appear similar to those observed in American Indian children
vaccinated with 7-valent PCV for serotypes 6B, 9V, and 14;
however, GMCs were higher in our study for serotypes 4, 18C and
19F and lower for serotype 23F [33].
There are several limitations to our study. We did not collect a
blood specimen immediately prior to dose 2 and therefore can
only comment on the post-dose 2 responses in relation to the post-
dose 1 antibody GMC and OPA GMT values. Group B subjects
were approximately four months older than Group A subjects
when the post-dose 2 blood sample was collected; this may have
obscured our ability to detect a significant difference between the
two dosing schedules. PCR may not differentiate perfectly between
non-typeable H. influenzae and H. haemolyticus; misclassification of
H. haemolyticus as non-typeable H. influenzae could have resulted in
an underestimation of vaccine effectiveness against carriage of
non-typeable H. influenzae. In coastal Kenya, nasopharyngeal
carriage of pneumococci is highest following the rainy season and
lowest in the dry season [34]. The timing of our study was such
that enrolment was conducted during the dry season and the day
180 NP swabs were collected just after the rainy season. However,
adjustment for season did not significantly change the outcomes.
The data from this study indicate that two doses of PHiD-CV
administered two to six months apart to children aged 12–59
months are well-tolerated, elicit immune responses including
functional antibodies and reduce nasopharyngeal carriage of
vaccine-type pneumococci. On balance, results suggest greater
impact on immune responses for two doses versus one dose;
however, countries considering ‘‘catch-up’’ immunization would
need to consider the local epidemiology to determine whether the
theoretical added value of a second dose justified the added cost in
terms of vaccine supply and delivery. Overall, these findings
suggest that countries choosing to conduct catch-up vaccination
with PHiD-CV could expect the vaccine to reduce disease in the
vaccinated cohort and contribute to indirect protection in
unvaccinated children and adults.
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